Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ctDNA-Guided Neoadjuvant Immunotherapy for dMMR/MSI-H Colon Cancer
NCT07841236Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Sep 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in colon cancer, sponsored by Fudan University. Primary endpoint: Pathological Complete Response Rate. Started Sep 2026; status: recruiting.
02
Conditions
colon cancer
Beyond the preview
Go deeper on NCT07841236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07841236.